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Inhibiting glycogen synthase kinase-3 (GSK-3) activity via pharmacological intervention
has become an important strategy for treating neurodegenerative and psychiatric disor-
ders. The known GSK-3 inhibitors are of diverse chemotypes and mechanisms of action
and include compounds isolated from natural sources, cations, synthetic small-molecule
ATP-competitive inhibitors, non-ATP-competitive inhibitors, and substrate–competitive
inhibitors. Here we describe the variety of GSK-3 inhibitors with a speciﬁc emphasis on
their biological activities in neurons and neurological disorders.We further highlight our cur-
rent progress in the development of non-ATP-competitive inhibitors of GSK-3.The available
data raise the hope that one or more of these drug design approaches will prove successful
at stabilizing or even reversing the aberrant neuropathology and cognitive deﬁcits of certain
central nervous system disorders.
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INTRODUCTION
The serine/threonine kinase GSK-3 is a conserved signaling
molecule with essential roles in diverse biological processes. Aber-
rant GSK-3 activity has been linked with several human diseases
including diabetes, inﬂammation, and neurodegenerative and psy-
chiatric disorders (Eldar-Finkelman, 2002; Doble and Woodgett,
2003; Gould et al., 2004b; Jope et al., 2007; Hernandez and Avila,
2008;Hooper et al., 2008;Hur andZhou,2010). This supported the
hypothesis that inhibition of GSK-3 will have therapeutic beneﬁt
and intensive efforts have been made in the search for and design
of selective GSK-3 inhibitors. The reported GSK-3 inhibitors are
of diverse chemotypes and mechanisms of action. These include
inhibitors isolated from natural sources, cations, and synthetic
small molecules. Regarding the mechanism of inhibition, we can
ﬁndATP-competitive inhibitors, non-ATP-competitive inhibitors,
and substrate–competitive inhibitors. A major challenge in the
ﬁeld is achieving speciﬁcity, and advanced structure-based compu-
tational studies are conducted to improve GSK-3 inhibitor speci-
ﬁcity and possibly to ensure targeting of speciﬁc GSK-3 isozymes.
Here we review the state of the art of GSK-3 inhibitors with focus
on their biological activities in neurons andneurological disorders.
We further highlight our current progress in the development of
non-ATP-competitive inhibitors of GSK-3 and their implications
in CNS disorders.
EVOLUTIONARY, STRUCTURAL, AND REGULATORY
FEATURES OF GSK-3-LEADINGS IN DRUG DESIGN
The importance of GSK-3 as a therapeutic target highlighted the
need for in depth understanding of different features of GSK-
3 with respect to sequence, structure, and regulation. GSK-3 is
highly conserved in the animal kingdom. In mammals, GSK-3 is
expressed as two isozymes: GSK-3α and GSK-3β. An alternative
splice variant of GSK-3β, GSK-3β2, has also been reported
(Mukai et al., 2002). GSK-3α and β share extensive similarities
in their catalytic domains, but differ in their N- and C-terminal
regions (Woodgett, 1990). In lower organisms such as choanoﬂa-
gellates, sea squirts, and nematodes, a single gene encodes
GSK-3 (Alon et al., 2011), whereas in vertebrates such as ﬁsh,
amphibians, reptiles, and lizards the two genes coding for GSK-
3α and β are identiﬁed; interestingly birds lack a copy of the
GSK-3α gene (Alon et al., 2011). The existence of two GSK-3
isozymes suggested that at least one of the isozymes tookonunique
functions tied to the emergence of vertebrates, likely related to
the development of highly ordered systems such as the central
nervous system (CNS). Recent studies had found certain physio-
logical differences between GSK-3 isozymes in functions related to
embryonic development, brain structure, and behavior; although
other studies clearly demonstrated redundant function for the two
isozymes (Hoeﬂich et al., 2000; Hernandez et al., 2002; Prickaerts
et al., 2006; Terwel et al., 2008; Kaidanovich-Beilin et al., 2009; Kim
et al., 2009;Mines et al., 2010; Alon et al., 2011; Soutar et al., 2011).
Our understanding of the distinct functions of GSK-3 isozymes
in neuronal systems and, in particular, their relative contributions
to neuropathologies is far from clear. This is of particular impor-
tance as we seek to determine the worthiness of development of
isozyme-speciﬁc inhibitors.
Like other protein kinases, GSK-3 is composed of a conserved
catalytic domain folded into a bi-lobal architecture with a smaller
N-terminal lobe responsible forATP binding and a larger, globular
C-terminal domain that contains the conserved “activation loop”
important for the kinase activity (Hanks and Hunter, 1995; Tay-
lor et al., 1995). Tyrosine residue located within the activation
loop is essential for full activation of GSK-3, and this process is a
chaperone-dependent auto-phosphorylation event (Hughes et al.,
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1993; Cole et al., 2004; Lochhead et al., 2006). GSK-3 activity is
further regulated by regions outside the catalytic domain. Its N-
terminal end contains a highly conserved RPRTTSF motif that
acts as an auto-inhibitory pseudosubstrate when phosphorylated
at serine (Frame and Cohen, 2001; Ilouz et al., 2008). Another site
located within the C-terminal region of GSK-3β (Thr 390) was
recently identiﬁed as an inhibitory site (Thornton et al., 2008). In
some instances, GSK-3 activity is also regulated via interactions
with regulatory proteins. For example, GSK-3 interacts with pre-
senilin proteins that, in turn, may regulate the production of the
Alzheimer’s amyloid beta peptide (Aβ; Phiel et al., 2003). Interac-
tion of GSK-3 with the scaffold protein Axin regulates the stability
of the Wnt signaling effector β-catenin (Ikeda et al., 1998; Wu and
Pan, 2011). FRAT/GBP competes with Axin and inhibits GSK-3
activity toward β-catenin (Yost et al., 1998). Axin and FRAT bind
to GSK-3 via a similar hydrophobic patch located within the C-
terminal region of GSK-3 (Fraser et al., 2002), this interaction
has been exploited for inhibitor design (Hedgepeth et al., 1999;
Thomas et al., 1999). Finally, the intracellular distribution of GSK-
3 isozymes is differentially regulated (Diehl et al., 1998; Bijur and
Jope, 2003; Meares and Jope, 2007; Caspi et al., 2008; Adachi et al.,
2011; Azoulay-Alfaguter et al., 2011; Wu and Pan, 2011). Hence,
GSK-3 function can be regulated at many levels, which in turn,
may be exploited in development of selective GSK-3 inhibitors.
Unlike other protein kinases, GSK-3 is constitutively active
in resting conditions and is inhibited in response to upstream
signals. It can be inhibited or over-activated by diverse post-
transductional modiﬁcations such as phosphorylation in response
to upstream signals (Eldar-Finkelman, 2002). In addition, GSK-3
shows a unique preference in substrate recognition as it requires
pre-phosphorylation of its substrates in the context of SXXXS(p)
(Woodgett and Cohen, 1984; Fiol et al., 1994). Crystallographic
studies of GSK-3β identiﬁed a phosphate binding pocket com-
prisedof three basic residues,Arg 96,Lys 205,andArg 189, that pre-
sumably binds the phosphorylated substrate (Dajani et al., 2001;
ter Haar et al., 2001). Phosphorylation of GSK-3-downstream
targets typically results in attenuation of the signaling pathway
and/or inhibition of the substrate’s activity. In neurons, GSK-3 is
intimately involved with control of apoptosis, synaptic plasticity,
axon formation, and neurogenesis (Crowder and Freeman, 2000;
Jiang et al., 2005; Yoshimura et al., 2005; Kim et al., 2006; Zhao
et al., 2007; Muyllaert et al., 2008; Hur and Zhou, 2010). In vivo
studies indicate that over-activity of GSK-3 results in adverse
effects. This over-activity should be produced by an increase in
GSK-3 expression or by an imbalance of its phosphorylation
state leading to a super-active enzymatic state. Transgenic animals
that overexpress GSK-3 display alterations in brain size, impaired
long-term potentiation (LTP), and deﬁcits in learning and mem-
ory (Lucas et al., 2001; Hernandez et al., 2002; Spittaels et al.,
2002; Hooper et al., 2008). These animals also have characteristics
typical of Alzheimer’s disease such as hyperphosphorylation of
tau and enhanced production of Aβ peptide (Lucas et al., 2001;
Phiel et al., 2003; Engel et al., 2006; Rockenstein et al., 2007). In
addition, data from pharmacological and genetic models impli-
cate GSK-3 activity in mood behavior and indicate that elevated
GSK-3 activity is associated with manic and depressive behavior
(Gould et al., 2004a; Kaidanovich-Beilin et al., 2004; O’Brien et al.,
2004; Prickaerts et al., 2006; Beaulieu et al., 2008; Mines et al.,
2010; Polter et al., 2010). Finally, abnormal regulation of GSK-3
activity was reported in patients with Alzheimer’s disease, amy-
otrophic lateral sclerosis (ALS), major depression, schizophrenia,
and bipolar disorder (Kozlovsky et al., 2002; Hu et al., 2003b; Hye
et al., 2005; Karege et al., 2007; Lovestone et al., 2007; Pandey et al.,
2010; Saus et al., 2010; Forlenza et al., 2011). Hence, increasing
efforts are focused on development of selective GSK-3 inhibitors
able to modulate this abnormal over-activity.
SMALL METAL CATIONS AS GSK-3 INHIBITORS
The cation lithium was the ﬁrst “natural” GSK-3 inhibitor dis-
covered (Klein and Melton, 1996; Stambolic et al., 1996). Lithium
(meaning lithium salts) is amood stabilizer long used in treatment
of bipolar disorders. Lithium inhibits GSK-3 directly by com-
petition with magnesium ions (Klein and Melton, 1996; Ryves
and Harwood, 2001) and indirectly via enhanced serine phos-
phorylation and autoregulation (De Sarno et al., 2001; Zhang
et al., 2003; Kirshennboim et al., 2004). Lithium has been widely
used in many studies as a pharmacological inhibitor of GSK-3;
these demonstrated that lithium produces similar biological con-
sequences as inhibition of GSK-3 via other means. For example,
treatment with lithium increases cellular β catenin levels (Stam-
bolic et al., 1996; O’Brien and Klein, 2009), reduces tau phos-
phorylation at GSK-3 epitopes in neurons (Noble et al., 2005),
activates glycogen synthase (Cheng et al., 1983), and promotes
embryonic axis duplication (Klein andMelton, 1996). Lithiumhas
striking morphological effects on neurons including a reduction
in axon length, increase in growth cone area, and an increase in
synapse formation (Burstein et al., 1985; Takahashi et al., 1999;
Owens et al., 2003; Kim and Thayer, 2009). The therapeutic
range of lithium is 0.5–1.5mM, and its IC50 toward GSK-3 is
1–2mM (Klein and Melton, 1996), suggested that lithium may
clinically inhibit GSK-3. Indeed, numerous studies have evaluated
the therapeutic activity of lithium in various neuronal systems,
and veriﬁed a profound effect of lithium in neuroprotection
against variety of insults in apoptotic and brain injury para-
digms (Bijur et al., 2000; Hongisto et al., 2003; Perez et al.,
2003; Williams et al., 2004; Jin et al., 2005; Wada et al., 2005;
Brewster et al., 2006; Chuang and Manji, 2007; Mathew et al.,
2008).
Lithium has been then tested in Alzheimer’s and related neu-
rodegenerative models. These studies demonstrated that lithium
blocks amyloid precursor protein (APP) deposits and reduces Aβ
secretion in cells and transgenic mice overexpressing APP (Sun
et al., 2002; Phiel et al., 2003; Rockenstein et al., 2007). Treat-
ment with lithium also prevented Aβ neurotoxicity in rat brain
(De Ferrari et al., 2003) and reduced tauopathy in transgenic
mice overexpressing human mutant tau (Noble et al., 2005; Cac-
camo et al., 2007). Lithium was shown to provide therapeutic
beneﬁt in models of epileptic neurodegeneration (Busceti et al.,
2007), motor performance in Huntington’s disease (Wood and
Morton, 2003), and hippocampal neuropathology and neuro-
logical functions in spinocerebellar ataxia type 1 (SCA1; Watase
et al., 2007). However, some studies reported that lithium had
no effect on tau phosphorylation, Aβ loads, and neuroprotec-
tion (Ghribi et al., 2003; Song et al., 2004; Caccamo et al.,
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2007). These could be due to differences in the experimental
sets (e.g., age, dose, time of treatment etc.) used in the dif-
ferent studies. Several clinical trials with lithium in AD and
elderly patients have been conducted but results are not conclu-
sive. Chronic treatment with lithium yielded positive results in
dementia patients (Havens and Cole, 1982) and improved cog-
nition and memory scores (MMSE) in patients receiving the
drug as compared to non-treated patients (Terao et al., 2006).
In AD patients, lithium reversed the reduction in brain-derived
neurotrophic factor (BDNF) serum concentrations (Leyhe et al.,
2009) and reduced the prevalence of AD in elderly patients with
bipolar disorder (Nunes et al., 2007). A different clinical study
found that treatment with lithium slowed the progression in
ALS (Bedlack et al., 2008) via autophagy-induced degradation of
aggregate-prone proteins (Bedlack et al., 2008). Other clinical tri-
als, however, did not conﬁrm the ability of lithium to prevent
dementia or improve cognition or to reduce tau phosphorylation
or Aβ levels in AD patients (Pachet and Wisniewski, 2003; Dunn
et al., 2005; Hampel et al., 2009). In addition, lithium had toxic
side effects in some elderly patients (Macdonald et al., 2008), and
studies with lithium were thus discontinued (Tariot and Aisen,
2009).
Other metal ions such as beryllium, zinc, mercury, and cop-
per are potent GSK-3 inhibitors (Ilouz et al., 2002; Ryves et al.,
2002). Interestingly, these cations are more potent inhibitors of
GSK-3 than lithium (IC50 in the micromolar concentration range
as compared to the IC50 of lithium which is within the millimolar
concentration range). Of particular interest is the trace element
zinc, that unlike lithium, and other metal ions is naturally found
in the body tissues. Zinc inhibits GSK-3 in the low micromolar
range (IC50 = 15μM) and elevates cellular β-catenin levels (Ilouz
et al., 2002). It is noteworthy that zinc levels are linked with major
depression and mental functions. In animal models, zinc deﬁ-
ciency results in increased depressive- and anxiety-like behaviors
(Kroczka et al., 2001; Tassabehji et al., 2008), and treatment with
zinc produces anti-depressive like activity in the mouse forced
swimming test (FST) model (Kroczka et al., 2001). Hypozincemia
is often detected in patients with major depression, and dietary
supplementation of zinc improves symptoms of depression (Bod-
nar and Wisner, 2005; Nowak et al., 2005). Hence, it is tempting
to speculate that the therapeutic activity of zinc in mood behavior
and other cognitive symptoms is mediated by its ability to inhibit
GSK-3. However, zinc is a co-factor of many enzymes and, like
lithium,may initiatemany cellular effects independently of GSK-3.
Still, research with lithium and zinc may further our understand-
ing of the biological functions of GSK-3 in man. Worth mention-
ing is also the indirect GSK-3 inhibition produced by the inorganic
salt sodium tungstate (Gómez-Ramos et al., 2006). As a conse-
quence of the GSK-3 inactivation, the phosphorylation of several
GSK-3 dependent sites of the microtubule tau protein decreases
(Gómez-Ramos et al., 2006). This fact points to a new potential
drug for treatment of AD. Remarkably, this compound has a low
toxicity proﬁle and is currently in phase I of clinical trials as an
antiobesity agent. Altogether, although mechanisms of action is
not fully clear, these cations may serve as a stepping stone for
development of new GSK-3 inhibitors that mimic their inhibitory
paradigms.
ORGANIC MOLECULES AS GSK-3 INHIBITORS
Much effort is done in the discovery and development of GSK-
3 inhibitors in the last years being a very active ﬁeld of research
for academic centers and pharmaceutical companies. Nowadays,
several chemical families have emerged as GSK-3 inhibitors,
including great chemical diversity. Some of these GSK-3 inhibitors
have synthetic origin but others have been derived directly or indi-
rectly from small molecules of natural origin. Worth mentioning
is the fact that the marine environment has been shown recently
to provide a source of chemical structures with promising bio-
logical activities for CNS diseases. In fact, marine invertebrates
have played a prominent role in the generation of novel GSK-3
inhibitors.
The number of small molecule GSK-3 inhibitors is continu-
ously increasing with most in the early discovery phase. Here, we
mainly focus on the GSK-3 inhibitors that have been tested in
biological systems. Collectively, these studies provided compelling
evidence of the speciﬁc roles of GSK-3 inneuronal functions under
both normal and pathological conditions. Generally speaking,
inhibition of GSK-3 has profound effects on neuroprotection, self
renewal and pluripotency in embryonic stem (ES) cells, axonal
morphogenesis, and mood behavior. As kinase selectivity is one of
the main hazards in the development of this class of therapeutic
agents, we will discuss GSK-3 inhibitors based on their ability to
compete or not with ATP.
GSK-3 ATP-COMPETITIVE INHIBITORS FROM NATURAL RESOURCES
Many of this kind of GSK-3 inhibitors isolated frommarine organ-
isms were identiﬁed during the search for inhibitors for cyclin-
dependent protein kinases (CDKs) with anti-tumor activity. The
dual activity of these inhibitors (and others) toward GSK-3 and
CDKs is a direct result of their structural similarity within the
ATP-binding domain (about 86% sequence similarity).
The bis-indole indirubin isolated from the traditional Chi-
nese medicine for treatment of myelocyte leukemia was initially
characterized as a CDK inhibitor and then found to be a potent
GSK-3 inhibitor (Hoessel et al., 1999; Leclerc et al., 2001). It
inhibits both protein kinases within the nanomolar concentra-
tion range. The indirubin analogs that were synthesized and tested
(collectively termed here “indirubins”) showed inhibitory activ-
ity toward both GSK-3 and CDKs (Leclerc et al., 2001; Meijer
et al., 2003). The indirubin analog 6-bromoindirubin, isolated
from a marine invertebrate, the mollusk known as “Tyrian pur-
ple,” showed a certain selectivity toward GSK-3 over CDKs (Meijer
et al., 2003). Accordingly, a synthetic cell-permeable derivative, 6-
bromoindirubin-3′-oxime (6BIO; Figure 1), was developed and
was about 16-fold more selective for GSK-3 relative to CDKs
(Meijer et al., 2003; Polychronopoulos et al., 2004). The biological
activity of 6BIO has been evaluated in several neuronal systems. It
reduced tau phosphorylation in cultured cortical neurons (Mar-
tin et al., 2009), and inhibited neurite outgrowth in cerebellar
and embryonic or postnatal dorsal root ganglion (DRG) neurons
(Kim et al., 2006; Alabed et al., 2011). This effect appeared to be
dependent on the degree of GSK-3 inhibition, as a weak inhi-
bition of GSK-3 promoted axon branching (Kim et al., 2006).
6BIO enhanced self renewal and pluripotency in human ES cells
(Sato et al., 2004), via its ability to act as a Wnt mimetic (Sato
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FIGURE 1 | SomeATP-competitive GSK-3 inhibitors with potential for CNS disorders. (A) Isolated from marine organisms. (B) Small molecules from
organic synthesis programs.
et al., 2004).Additional studieswith indirubins demonstrated their
ability to provide neuroprotection against kainic acid, MPTP (1-
methyl-4-phenyl-1,2,3,6-tetrahydropyridine), and trophic depri-
vation (Hongisto et al., 2003; Jin et al., 2005; Wang et al., 2007;
Magiatis et al., 2010). In vivo systemic administrationof indirubin-
3′-oxime to APP/Presenilin-1 transgenic mice, a established AD
model, attenuated many AD symptoms including tau hyperphos-
phorylation,Aβ accumulation, inﬂammation, and spatialmemory
deﬁcits (Ding et al., 2010). In contrast, treatment with indirubin-
3′-oxime did not reduce tau phosphorylation in cultured neurons
or in the rat brain (Selenica et al., 2007). These discrepancies could
be due to the limited bioavailability of indirubin-3′-oxime, which,
like other indirubins, has limited water solubility (Leclerc et al.,
2001). Recent work reported the synthesis of additional indirubin
derivatives with improved water solubility (Vougogiannopoulou
et al., 2008). Their biological activity has not yet been reported.
Sponges (Porifera), as the best known source of bioactive
marine natural products in metazoans, play a signiﬁcant role in
marine drug discovery and development. The alkaloids debromo-
hymenialdisine (DBH) and hymenialdisine (HD), which contain
both bromopyrrole and guanidine groups (Williams and Faulkner,
1996; Figure 1) were originally isolated from sponges belonging
to the Agelasidae, Axinellidae, and Halichondridae. HD structure
was established using X-ray crystallography (Cimino et al., 1982)
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and it is a potent protein kinase inhibitor targetingGSK-3β, CDKs,
MEK1, CK1, and Chk1 (Tasdemir et al., 2002; Sharma and Tepe,
2004) among others. In addition, HD has the ability to inhibit
GSK-3β in vivo and also blocks the in vivo phosphorylation of the
microtubule-binding protein tau at sites which are hyperphos-
phorylated by GSK-3 in AD (Meijer et al., 2000). As observed with
other GSK-3 inhibitors, HD, and derivatives act in competition
with ATP (Wan et al., 2004). Recently, it has been shown that HD
and DBH are stored in spherulous cells from Axinella sp. (Song
et al., 2011), which can help to deﬁne the bioactive production
strategy in terms of sponge aquaculture.
The potent activity of HD as a competitive kinase inhibitor
aroused interest in synthesizing a pyrrole-azepin-8-one ring sys-
tem bonded to a glycocyamidine ring scaffold (Nguyen and Tepe,
2009). Crystallographic data of the HD complex with CDK2,
led to the rational development of new analogs with increased
potency and selectivity over GSK-3, CDK5, and CDK1. Moreover,
using different docking methods and molecular dynamics simu-
lation, the structural determinants that govern target selectivity
on HD derivatives has been studied, explaining the signiﬁcant
inhibitory effect on GSK-3 of the related HD metabolite dibro-
mocantharelline (Zhang et al., 2011). The speciﬁc residue Cys199
near the binding site of GSK-3 provides new clues for the design
of potent and selective inhibitors.
Meridianins are brominated 3-(2-aminopyrimidine)-indoles,
which are isolated from the tunicate Aplidium meridianum, an
ascidian collected near the South Georgia Islands. These com-
pounds inhibit various protein kinases such as CDKs, GSK-3,
PKA, and CK1 (Gompel et al., 2004; Figure 1). The ability of
Meridianins to prevent cell proliferation and to induce apopto-
sis, demonstrated their ability to enter cells and to interfere with
the activity of kinases important for cell division and cell death
(Gompel et al., 2004). Different medicinal chemistry approaches
were employed to prepare more selective GSK-3 inhibitors (Akue-
Gedu et al., 2009). However, in all cases, they were most potent
toward CDKs, and inhibition of GSK-3 was marginal (Echalier
et al., 2008).
SYNTHETIC, ATP-COMPETITIVE GSK-3 INHIBITORS
Among the ﬁrst synthetic small molecule GSK-3 inhibitors
reported were the purine analogs, the aminopyrimidines,
developed by Chiron. The potent inhibitors CHIR98014
(CT98014), CHIR98023 (CT98023), CHIR99021 (CT99021) (col-
lectively termed here the CHIRs) inhibit GSK-3 within the
nanomolar concentration range (Ring et al., 2003; Figure 1).
Systemic analysis that proﬁled protein kinase inhibitors also con-
ﬁrmed the high selectivity of CHIRs toward GSK-3 (Bain et al.,
2003, 2007). A limited number of studies have tested CHIRs in
neuronal systems (these compounds had been chieﬂy tested in
diabetic models). They showed that CHIRs potently reduced tau
phosphorylation in cultured neurons and the rat brain (Selenica
et al., 2007). In addition, treatment with CHIRs inhibited neurite
outgrowth in cerebellar and DRG neurons (Alabed et al., 2011)
andblockedNMDA-mediated long-termdepression (LTD) in hip-
pocampus slices (Peineau et al., 2009), indicating an unexpected
role of GSK-3 in LTD maintenance (Peineau et al., 2009). In agree-
ment with the 6BIO studies, CHIRs enhanced self renewal and
pluripotency in mouse ES cells mimicking the activation of Wnt
signaling pathway (Ying et al., 2008; Li et al., 2011). Finally, CHIRs
reduced neuronal death in a cerebral ischemia rat model (Kelly
et al., 2004), and enhanced the levels of the survival motor neu-
ron protein (SMN) in spinalmuscular atrophy (SMA;Makhortova
et al., 2011).
The arylindolemaleimides SB-216763 and SB-415286 are
highly selective GSK-3 inhibitors developed by GlaxoSmithKline
that inhibit GSK-3 within the low nanomolar concentration range
(collectively termed here SBs; Coghlan et al., 2000; Figure 1). A
Numberof studies demonstrated theneuroprotective effects of SBs
against variety of pro-apoptotic conditions including inhibition of
the PI3 kinase/Akt survival pathway, trophic deprivation,Aβ toxic-
ity, heat shock, ethanol, NMDA excitotoxicity, and polyglutamine
toxicity caused by the Huntington’s disease protein (Bijur et al.,
2000; Cross et al., 2001; Culbert et al., 2001; Carmichael et al.,
2002; Facci et al., 2003; Hongisto et al., 2003, 2008; Takadera
and Ohyashiki, 2004; Hu et al., 2009). In addition, SB-216763
was shown to inhibit axon growth in postnatal and embryonic
DRG neurons (Owens et al., 2003; Alabed et al., 2011). On the
other hand, different studies reported that SB-216763 induced
the formation of multiple long axons in hippocampal, cerebel-
lar granular (CG), and DRG neurons (Padilla et al., 1997; Jiang
et al., 2005;Yoshimura et al., 2005; Seira et al., 2011). Furthermore,
it improved axon regeneration in lesioned neurons (Seira et al.,
2011). Apparently it appeared that axon fate is dependent on the
degree of inhibition of GSK-3, namely, strong inhibition of GSK-3
with high concentration of inhibitor inhibited axon growth, while
weak inhibition promoted axon branching (Kim et al., 2006). An
alternative explanation for these discrepancies relies on different
culture length (Jiang et al., 2005). In any event, it has been clearly
demonstrated that GSK-3 regulates neurite polarity and neurite
outgrowth. The therapeutic activity of SBs has been further tested
in several in vivo models. SB-216763 reduced ischemic cerebral
damage in mice subjected to middle cerebral artery occlusion
(Valerio et al., 2011), and enhanced locomotor recovery after spinal
cord injury (Padilla et al., 1997). Like CHIRs, treatment with SBs
inhibited NMDA-induced LTD (Peineau et al., 2009). In an AD
model of mice injected with Aβ peptide, SB-216763 reduced Aβ
neurotoxic effects including reduction in tau phosphorylation,
caspase-3, and the activity of the stress activated kinase JNK (c-Jun
N-terminal kinase; Hu et al., 2009). Administration of SB-216763
to disrupted-in-schizophrenia-1 (DISC1) knockdown mice ame-
liorated schizophrenic symptoms such as depressive behavior and
hyper-locomotion (Mao et al., 2009). In the postnatal rat model,
administration of SB-216763 reduced tau phosphorylation in
the hippocampus (Selenica et al., 2007). In one of these stud-
ies, however, SB-216763 produced neurodegenerative-like effects
and behavior deﬁcits in healthy mice (Hu et al., 2009). This
demonstrates that over-inhibition of GSK-3 may result in condi-
tions that prevent neurons from operating normally. Thus, GSK-3
inhibitors should be used preferentially in pathologies associated
with elevated GSK-3 activity. Finally, additional maleimide deriv-
atives were recently identiﬁed by phenotypic screen for defects in
zebraﬁsh embryogenesis (Zhang et al., 2011). These compounds
were potent GSK-3 inhibitors (Zhang et al., 2011), but their
biological activity remains to be tested in relevant systems.
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The amino thiazoleAR-A014418developedbyAstraZenecawas
shown to be a selective inhibitor toward GSK-3 when compared to
other protein kinases including CDKs (Bhat et al., 2003; Figure 1).
In their initial study, Bhat et al. (2003) showed that AR-A014418
was neuroprotective in apoptotic conditions induced by inhibition
of PI3 kinase and prevented neurodegeneration in hippocampal
slices exposed to Aβ peptide. Consistent with studies using SBs
and 6BIO (Owens et al., 2003; Kim et al., 2006; Alabed et al.,
2011), treatment with AR-A014418 prevented axon elongation in
hippocampal neuronal culture (Shi et al., 2004). AR-A014418 has
also been examined in behavior models. It was shown to pro-
duce an anti-depressive like behavior in the mouse FST (Gould
et al., 2004a; Silva et al., 2008) and, in a manic behavior model
of amphetamine-induced hyperactivity, it reduced manic activity
(Kalinichev and Dawson, 2011). These results suggest that inhi-
bition of GSK-3 may be beneﬁcial in both depressive and manic
episodes. Finally, in JNPL3 transgenic mice overexpressing mutant
human tau, AR-A014418 reduced levels of aggregated insoluble
tau in the brainstem (Noble et al., 2005), and, in an ALS trans-
genic mouse model, AR-A014418 attenuated motor neuron death
and improved cognition (Koh et al., 2007). Yet, unexpectedly,
AR-A014418 showed no effect on tau phosphorylation in the cor-
tex or hippocampus in the postnatal rat model (Selenica et al.,
2007). A structurally closed related compound AZD-1080 entered
into clinical trials phase I for AD in 2006, but unfortunately the
development has been discontinued.1
The group of paullone compounds, in particular kenpaullone
and alsterpaullone, are widely used in various experimental set-
tings as GSK-3 inhibitors (Figure 1). Paullones are fused tetra-
cyclic compounds that inhibit both GSK-3 and CDKs within the
nanomolar concentration range (Schultz et al., 1999; Leost et al.,
2000). A structurally similar compound, 1-azakenpaullone, is a
more selective GSK-3 inhibitor (Kunick et al., 2004). Its derivative
cazpaullone (9-cyano-1-azapaullone; Figure 1) has been recently
characterized as a selective GSK-3 inhibitor (Stukenbrock et al.,
2008). Both alsterpaullone and kenpaullone prevented neuron cell
death in response to variety of insults including trophic depriva-
tion, thapsigargin treatment, and mitochondrial stress (Takadera
and Ohyashiki, 2004; Mishra et al., 2007; Petit-Paitel et al., 2009;
Skardelly et al., 2011). Alsterpaullone was shown to reduce tau
phosphorylation in cultured neurons (Leost et al., 2000; Selenica
et al., 2007), and to block NMDA-induced LTD in hippocampal
slices (Peineau et al., 2008). Kenpaullone decreased Aβ produc-
tion in cells overexpressing APP (Phiel et al., 2003) and pro-
moted differentiation of precursor cells into dopamine neurons
(Castelo-Branco et al., 2004). This last supported the use of GSK-
3 inhibition in treatment of Parkinson’s disease (Castelo-Branco
et al., 2004). Recent work implicated a role for GSK-3 in SMA
(Makhortova et al., 2011). Apparently, a search for small mole-
cules that elevate the expression levels of SMN identiﬁed GSK-3
inhibitors as potential agents. Treatment with alsterpaullone veri-
ﬁed this observation and showed that alsterpaullone slowed down
the degradation of SMN in SMA human ﬁbroblasts (Makhortova
et al., 2011). Furthermore, the death of motor neurons induced
1http://www.astrazeneca.com/article/511390.aspx, Accessed on April 29, 2008
by depletion of SMN was rescued by alsterpaullone (Makhortova
et al., 2011). This study is a ﬁrst indication of a therapeutic poten-
tial of inhibition of GSK-3 in SMA (Makhortova et al., 2011).
Reports of alsterpaullone or kenpaullone in in vivo systems are
limited. One study demonstrated the ability of alsterpaullone to
reduce tau phosphorylation in the rat brain (Selenica et al., 2007).
Additional compounds were recently described as dual
CDK/GSK-3 inhibitors. These include the purine derivatives pyra-
zolo [3,4-b] quinoxalines (Ortega et al., 2002), the pyrazolo[3,4-
b]pyridine ring system (Chioua et al., 2009), the 9-oxo-thiazolo
[5,4-f] quinazoline-2-carbonitrile derivatives (Loge et al., 2008),
and the thiazolo[5,4-f]quinazolin-9-ones (Testard et al., 2006).
Aloisines (6-phenyl[5H ]pyrrolo[2,3-b]pyrazines) are a different
class of dual CDK/GSK-3 inhibitors that inhibit the two kinases
in the sub-micromolar range (Mettey et al., 2003). Aloisine A
(Figure 1) is the most potent of those analogs tested and showed
anti-proliferative effects in differentiated postmitotic neurons
(Mettey et al., 2003). A series of bisindolylmaleimides were identi-
ﬁed as potent GSK-3 inhibitors and were shown to enhance mouse
ES cells self renewal in the presence of the leukemia inhibitory fac-
tor (LIF; Bone et al., 2009). Recent work identiﬁed TWS119, a
4,6-disubstituted pyrrolopyrimidine (Figure 1), from a pheno-
typic cellular screen for compounds with the ability to induce
neuronal differentiation of pluripotent mouse ES cells; the com-
pound proved to be a GSK-3 inhibitor (Ding et al., 2003). This
result contrasts with earlier studies that demonstrated mainte-
nance of pluripotency by other GSK-3 inhibitors (Sato et al., 2004;
Ying et al., 2008). These differences could be due to differences
between mouse and human ES cells, culture conditions, or dif-
ferences in the developmental stages derivation (Welham et al.,
2007). Finally, a novel series of macrocyclic polyoxygenated bis-
7-azaindolylmaleimides were shown to be highly selective toward
GSK-3 (Kuo et al., 2003; Shen et al., 2004). Their biological activity
remains to be further elucidated.
Collectively, studies with ATP-competitive inhibitors veriﬁed
that GSK-3 is essential for maintenance of normal neuronal
activities, but also demonstrated an important role for GSK-3
in the etiological mechanisms of neurodegeneration and psychi-
atric disorders. Crystallographic data identiﬁed speciﬁc interac-
tions within the ATP-binding pocket and with additional residues
located at the surface of the C-lobe. These include Asp 133, Arg
141 Gln185, Asp200, and Arg220 and the conserved salt bridge
of Lys 85/Glu 97 (Figure 3A). However, the limited speciﬁcity of
ATP-competitive inhibitors is a serious drawback as demonstrated
in series of studies that proﬁled many protein kinase inhibitors
(Davies et al., 2000; Bain et al., 2003, 2007). It is possible that the
high toxicity of this type of drugs prevented entering into the clin-
ical phase or resulted in a failure in clinical treatments. It may be
possible to improve speciﬁcity by exploitingunique featureswithin
the ATP-binding fold of GSK-3, but this strategy requires further
validation. As a last caveat, the dual inhibition of GSK-3 and CDKs
may be not disadvantageous. CDK5 which is largely restricted to
neurons, is essential for regulation of many neuronal functions
(Jessberger et al., 2009), and its aberrant activity has been impli-
cated in variety of neurodegenerative conditions (Cruz and Tsai,
2004). CDK5 also serves as the “priming kinase” that phosphory-
lates prior its phosphorylation by GSK-3 (Li et al., 2006; Plattner
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et al., 2006). Thus, inhibition of both GSK-3 and CDK5 may be
of therapeutic beneﬁt, and the use of such dual activity inhibitors
should not be discouraged until further evaluation in preclinical
models.
SYNTHETIC, NON-ATP-COMPETITIVE GSK-3 INHIBITORS
As we have highlighted above, there are many compounds with
different scaffolds able to inhibit GSK-3 in an ATP-competitive
manner; these compounds may have adverse secondary effects if
used in chronic treatment. The human kinome has more than
500 protein kinases that share a high degree of homology in the
catalytic site, and in particular, within the ATP-binding pocket.
Achieving kinase selectivity is one of the main challenges in the
search and design of protein kinases inhibitors (Eglen and Rei-
sine, 2009). ATP non-competitive GSK-3 inhibitors are likely to
be more selective than those that inhibit ATP binding, since they
should bind to unique regions within the kinase providing a more
subtle modulation of kinase activity than simply blocking ATP
entrance. This point is of utmost importance for GSK-3 modula-
tion as a therapeutic approach, because only the aberrant GSK-3
activity should be inhibited.
There are different chemical families of organic compounds
reported in the literature that do not compete with ATP in their
GSK-3 inhibition and different binding modes to the enzyme have
been described. The ﬁrst reported family was the small hetero-
cyclic thiadiazolidinones (TDZD) family (Martinez et al., 2002;
Figure 2A). Although their mechanism of action has not yet been
experimentally conﬁrmed, a possible role has been postulated for
an interaction with cysteine 199, a key residue located in the active
site of GSK-3 (Mazanetz and Fischer, 2007). TDZD did not show
inhibition over various kinases including PKA, PKC, CK-2, and
CDK1/cyclin B. Treatment of primary culture neuronal cells with
TDZD reduced tau phosphorylation, and treatment with diverse
TDZDs such as NP00111 (Figure 2A), NP031112, NP03115,
FIGURE 2 | ATP non-competitive GSK-3 inhibitors with potential for CNS disorders. (A) Small molecules from organic synthesis programs. (B) Natural
compounds isolated from marine organisms. (C) Peptide competitive with substrate.
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produced neuroprotective and antidepressant activities in several
animals models (Luna-Medina et al., 2007; Rosa et al., 2008a,b).
With these others positive data, safety regulatory studies of one
TDZD candidate was donewith the aim to determinate the human
dose. Very relevant for the translation from the bench to the treat-
ment of AD patients are the results obtained in the chronic oral
treatment for 3months performed with TDZD compound named
NP-12, to the double transgenic APP× tau rodent model (Ribe
et al., 2005). Treatment with NP-12 improved cognitive perfor-
mance in the Morris water maze test, while all histopathological
features related to AD pathology such as beta-amyloid plaque
load, tau hyperphosphorylation, gliosis, and neurons death were
signiﬁcantly reduced (Sereno et al., 2009). Of interest is the obser-
vation regarding the increase in insulin growth factor-1 (IGF-1)
in mice brains of both on wild type and APP×PS1 mice, after
an acute oral treatment with NP-12 for 5 days (Bolos et al., 2011).
IGF-1 is a potent neurotrophic peptide with therapeutic value for
manyneurodegenerative diseases includingADpathology (Torres-
Aleman, 2007). These increased IGF-1 levels in mice would mean
that there is not only a direct action of GSK-3 inhibitors on the
brain, but, there is also an effect on some peripheral signaling
pathways (as activation of the IGF-1 transporter megalin), that
could be modiﬁed with this innovative treatment improving the
AD pathology.
Much of thework done in the hit-to-lead process, and lead opti-
mization of TDZD heterocyclic family has been reported recently
(Martinez et al., 2008). Two molecules have been well character-
ized. The ﬁrst is TDZD-8, which is one of the pharmacological
tools frequently used to study the biological and pathological roles
of GSK-3 in cellular and animal models (Beaulieu et al., 2004;
Cuzzocrea et al., 2006; Lipina et al., 2011). The second molecule is
NP031112, also termedNP-12 or tideglusib. It is a brain permeable
small molecule currently used in clinical trials phase II for AD and
progressive supranuclear palsy (PSP).
Data from thephase IIa trial of tideglusibwere recently reported
and indicated a trend in improved cognitive abilities of the mild to
moderate AD patients treated for 24weeks (del Ser, 2010). The
phase IIb trial for AD2 is ongoing with more than 20 centers
involved. FDA and EMEA have approved the orphan drug status
for the development of tideglusib in the rare tauopathy PSP3. The
TAUROS study is ongoing and results are expected to be ﬁnalized
by the end of 2011.
The second family of compounds known as ATP non-
competitive GSK-3 inhibitors is the halomethylketone (HMK)
derivatives (Conde et al., 2003) which have been recently described
as the ﬁrst irreversible inhibitors of this enzyme (Perez et al., 2009a;
Figure 2A). In this case, inactivation of the enzyme is due to the
formation of an irreversible covalent sulfur–carbon bond between
the key cysteine 199 located at the entrance to the ATP site of
GSK-3 and the HMK moiety (Perez et al., 2011).
HMKs are cell-permeable compounds. They are able to
decrease tau hyperphosphorylation on primary neurons cell
culture after 2 h of treatment (Perez et al., 2009a). They are rather
2http://clinicaltrials.gov/show/NCT01350362
3http://clinicaltrials.gov/ct2/show/NCT01049399?term=tideglusib&rank=1
selective in a wide protein kinase panel and its off-target activ-
ity were determined on different CNS receptors binding assays
without any signiﬁcant positive data (Perez et al., 2009a). There
are a couple of HMKs commercially available from different
commercial sources that conﬁrms the importance of this series
of compounds as pharmacological tools for the study of GSK-3
physiology and pathology in different cell models (Yasuda et al.,
2009).
NON-ATP-COMPETITIVE GSK-3 INHIBITORS FROM NATURAL
RESOURCES
Manzamines are complex β-carboline alkaloids isolated from
Indo-Paciﬁc sponges and characterized as having an intricate and
novel polycyclic system (Hu et al., 2003a). Following a discovery
program of GSK-3 inhibitors from marine sources, it was found
that manzamine A (Figure 2B) inhibits human GSK-3β in vitro
more than 70% at 25μM (Rao et al., 2006). In order to identify
the pharmacophore responsible for this new enzymatic inhibition,
the potential GSK-3 inhibition of carboline and ircinal A, which
can be considered the chemical precursors of manzamine A, were
tested. Both moieties are inactive in their ability to bind to GSK-
3, indicating the entire manzamine molecule is responsible for
this activity. To further assess the potential of manzamine A in
the treatment of AD, its ability to inhibit several different kinases
(GSK-3β, GSK-3α, CDK1, PKA, MAPK, and CDK5) and decrease
the hyperphosphorylation of tau protein mediated by GSK-3 in
human neuroblastoma cell cultures was investigated (Hamann
et al., 2007). ManzamineA speciﬁcally inhibits GSK-3β and CDK5
(the two key players in the hyperphosphorylation of tau protein
in AD) with IC50s of 10 and 1.5μM respectively; it is ineffective
toward others kinases tested (Hamann et al., 2007). Kinetic stud-
ies indicated an ATP non-competitive inhibition regarding GSK-3
(Hamann et al., 2007) while susbstrate competitive inhibition has
been recently proved experimentally (Palomo et al., 2011).
Treatment of SH-SY5Y cells in culture with manzamine A at
different concentrations (5, 15, and 50μM) resulted in a decrease
in tau phosphorylation at the GSK-3 epitope Ser 396 (Hamann
et al., 2007). as quantiﬁed by a speciﬁc ELISA sandwich method-
ology. Cell survival was determined in parallel by measuring LDH
release. ManzamineA constitutes a promising scaffold from which
more potent and selective GSK-3 inhibitors could be designed as
potential therapeutic agents for the treatment of diseasesmediated
by GSK-3 such as the AD (Wahba and Hamann, 2011). Recently a
potential binding site of manzamine A with GSK-3 was identiﬁed,
and this will provide new directions in substrate competitive drug
design (Peng et al., 2011).
Very recently extracts and compounds obtained from the
marine organism Ircinia sp., and, more particularly, the fura-
noterpenoids isolated from the Mediterranean sponges Ircinia
dendroides, Ircinia variabilis, and Ircinia oros, have been claimed
as inhibitors of GSK-3 (Alonso et al., 2005). Fractionation and
puriﬁcation of active components from these extracts, guided
by a GSK-3 inhibition assay, resulted in the isolation of fura-
nosesquiterpenoids as new GSK-3 inhibitors with potential use
as therapeutic agents. Palinurin and one unknown metabolite
called tricantin were mainly isolated (Figure 2B). Kinetic analy-
ses of isolated compounds were performed and showed that
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tricantin inhibits recombinant human GSK-3β with an IC50 value
of 7.5μM, whereas palinurin exhibited an IC50 value of 4.5μM.
They are cell-permeable inhibitors and described as ATP non-
competitive GSK-3 inhibitor able to reduce tau phosphorylation
in cell cultures (Alonso andMartinez, 2006). Total synthesis of pal-
inurin has been recently described providing a new source for this
lead compound (Perez et al., 2009b). Different studies have been
performed to determine structure activity relationships among a
series of congeneric molecules and the bioactive conformation has
been proposed (Ermondi et al., 2011). However, the binding mode
to GSK-3 remains unknown.
PEPTIDES AS SUBSTRATE–COMPETITIVE INHIBITORS
Peptides have also been described as potential protein kinase
inhibitors (Eldar-Finkelman andEisenstein,2009). Theuse of pep-
tides, which copy natural motifs that speciﬁcally inﬂuence kinase
activity and/or its intracellular interactions with associated part-
ners, may be a promising approach for selective inhibition of pro-
tein kinases. Although substrate–competitive inhibitors have often
been overlooked due their relative weak inhibition, they provide
numerous advantages over theATP-competitive inhibitors,mainly
in selectivity. This is due to the fact that substrate recognition and
types of interactions vary considerably among kinases, whereas
ATP-binding domains are structurally conserved. In the case
of GSK-3, the relatively weak afﬁnities of substrate–competitive
inhibitors, and, in general, ATP non-competitive inhibitors, may
be advantageous. GSK-3 is essential for many aspects of neuronal
function; hence, drastic inhibition may result in deleterious effects
(as has been observed with some of GSK-3 inhibitors). Further-
more, pathological GSK-3 over-expression does not exceed two to
threefold over normal levels. Thus, moderate-to-weak inhibition
of GSK-3 (about 50% inhibition) is actually a desired approach for
treatment of disorders associated with elevated activity of GSK-3.
Finally because substrate–competitive inhibitors aremore selective
thanATP-competitivemolecules, substrate–competitive inhibitors
may be a favorable choice for clinical use.
The speciﬁc requirement of GSK-3 for pre-phosphorylated
substrates supported the rational for the use of synthetic phospho-
rylated peptides as substrate–competitive inhibitors (Plotkin et al.,
2003). The peptide L803-mts (11 residues) is a cell-permeable
phosphorylated peptide derived from the GSK-3 substrate heat
shock factor-1 (HSF-1;Figure 2C) that is very selective and inhibits
cellular activity of GSK-3 within the low micromolar concen-
tration range (Plotkin et al., 2003). L803-mts showed biological
activity in diabetic models consisting with the paradigm of GSK-3
acting as a negative regulator of insulin signaling (Kaidanovich-
Beilin and Eldar-Finkelman, 2006; Rao et al., 2007). Recent work
further demonstrated the therapeutic activity of L803-mts in CNS
models. Like other GSK-3 inhibitors, L803-mts promoted axon
formation and elongation in hippocampal neurons (Kim et al.,
2006). It was also shown to provide neuroprotection effects in
neuron cultured cells exposed to 6-hydroxydopamine-induced
cell death (Chen et al., 2004). In vivo treatment with L803-mts
increased β-catenin levels in the mouse hippocampus and pro-
duced anti-depressive like activity in the FST (Kaidanovich-Beilin
et al., 2004). Administration of L803-mts in a traumatic brain
injury (TBI) model reversed depressive behavior in the injured
animals (Shapira et al., 2007). Finally, L803-mts conferred low tox-
icity in neurons as compared with other GSK-3 inhibitors (Kim
and Thayer, 2009).
Understanding of the mode of interaction of GSK-3 with its
substrates is necessary for effective design and development of
substrate–competitive inhibitors. A combined approach of muta-
genesis and computational protein–protein docking analyses iden-
tiﬁed a novel substrate-binding site within the catalytic core of
GSK-3β formed by Phe 67, Gln 89, Phe93, and Asn 95 (Ilouz et al.,
2006; Licht-Murava et al., 2011), and Asp 181 as an additional
binding site for the N-terminal pseudosubstrate (Ilouz et al., 2008;
Figure 3B). These residues are spatially located near the ATP-
binding site and the phosphate binding pocket that interacts with
the phospho-serine moiety of the substrate (Dajani et al., 2001;
ter Haar et al., 2001; Figure 3B). From studies of the binding
mode of L803-mts withGSK-3 it was found that the inhibitor- and
substrate-binding sites are not identical. Both substrate and L803-
mts interact with the phosphate binding pocket, but the substrate
interacts with the cavity bordered by Gln 89 and Asn 95, whereas
L803-mts mainly interacts with Phe 93 and with a hydrophobic
surface located away from the ATP-binding site (Licht-Murava
et al., 2011; Figure 3B). This clariﬁed our understanding of the
different binding modes of substrates and inhibitors. Whereas the
substrate requires appropriate alignmentwith the catalytic domain
to allow catalysis, the inhibitor does not require an exact posi-
tioning within the catalytic cleft. Contacts other than those used
by the substrate may be crucial for converting a substrate to an
inhibitor. Based on this idea, new L803-mts variants were synthe-
sized, and some were 3- to 10-fold better inhibitors than L803-mts
(Licht-Murava et al., 2011). Taken together, substrate–competitive
inhibitors of GSK-3 hold tremendous promise as potential thera-
peutics. An extensive understanding of molecular recognition of
GSK-3 with its substrates and inhibitors should provide the basis
for rational design and optimization of efﬁcient and high afﬁnity
substrate–competitive inhibitors.
A different example for peptide inhibitors are two peptides
derived from Frat (FRATide-39 residues) or Axin (Axin GID-25
residues) that compete withAxin binding toGSK-3,which in turn,
leads to activation of Wnt signaling pathway (Hedgepeth et al.,
1999;Thomas et al., 1999). TreatmentwithAxinGID inducedmul-
tiple axon formation in hippocampal neurons (Jiang et al., 2005),
and its exogenous expression in cerebellar granule neurons pro-
tected against trophic deprivation-induced cell death (Hongisto
et al., 2003). These results could suggest that GSK-3 inhibition-
mediated neuroprotection or axon formation involves activation
of Wnt signaling and or an increase in Axin non-bound GSK-3
pool (Hongisto et al., 2003). However, from the therapeutic point
of view, more relevant are small peptides.
PROSPECTIVE AND CHALLENGES
Cumulative data now suggest a promising future for GSK-3
inhibitors (Table 1). However, some concerns had been raised
regarding the potential toxicity of these compounds ranging from
hypoglycemia to tumorigenesis and neuron deregulation. Further-
more, GSK-3 is essential for life, and there is a concern that its
inhibition could prevent cells from operating normally. Never-
theless, it is worth mentioning that GSK-3 activity is elevated
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FIGURE 3 | GSK-3-interacting sites with ATP-competitive
inhibitors, substrates, and L803-mts. (A) Sites interacting with ATP or
ATP-competitive inhibitors are indicated. These interacting sites are located at
the interface within the N- and C-lobes of the catalytic domain. F67 (yellow)
locates the P-loop interacting with ATP (B) Distinct and overlapping element in
GSK-3 interaction with substrates and inhibitors. Sites interacting with
substrates: F67 (yellow), 89–95 loop (red), phosphate binding pocket
(P-binding pocket, blue). D181 (orange) interacts with the pseudosubstrate.
Sites interacting with L803-mts: F93 (within the 89–95 loop), hydrophobic
patch (V214, I217Y216 magenta), and the phosphate binding pocket (blue).
GSK-3 structure is based on PDB code 1gng and images were processed by
PyMol software.
in pathological conditions, thus, a smooth inhibition of GSK-3
able to restore down levels of activity to physiological ones would
be enough to produce an important therapeutic effects in unmet
diseases, being that point crucial for not produce adverse effects.
Evidently, treatment with GSK-3 inhibitors restored glucose
homeostasis and did not provoke hypoglycemia or hyperinusline-
mia in diabetic models. Activation of the proto-oncogenic mole-
cule β-catenin by inhibition of GSK-3 is another major concern
claiming that long-term inhibition of GSK-3 may promote cancer.
However, no direct in vivo evidence has indicated tumorigene-
sis upon administration of GSK-3 inhibitors. On the contrary, in
certain cancers GSK-3 inhibitors reduced cell proliferation and
enhanced cell death upon irradiation treatment. Compelling evi-
dence in this regard is the fact that treatment with the drug lithium
which has been used as standard therapeutic for the treatment of
bipolar disorder since the 1950s is not associated with increased
levels of tumorigenesis or deaths from cancer. Certainly the degree
of GSK-3 inhibition is a crucial element affecting toxicity, and a
weak to moderate inhibition of GSK-3 is an optimal therapeutic
approach.
GSK-3 inhibitors that are non-ATP-competitive provide
important beneﬁts in therapeutic use for several reasons. First of all
because, better kinase selectivity may be expected from inhibitors
that bind outside the ATP pocket, and secondly, because, this kind
of kinase inhibitors should have lower values of IC50, which in the
case of GSK-3 is not only beneﬁcial but also necessary to avoid tox-
icity. Thus, non-ATP-competitive GSK-3 inhibitors, which com-
prise covalent inhibitors, substrate–competitive inhibitors and
allosteric modulators, arise as the unique real potential drugs for
the treatment of at least chronic diseases as AD. An interesting
question in this regard is the feasibility in the design of selective
inhibitors toward GSK-3α or GSK-3β. The fact that the catalytic
domains of the two isozymes share more than 90% homology
suggests that inhibitors targeting this domain may not discrim-
inate between the two isozymes (as indeed is deduced in the
in vitro kinase assays). A different strategic approach exploiting
unique properties of GSK-3 isozymes such as protein–protein
interactions, distinct cellular localization etc. should be used in
development of such inhibitors. Hence, a better understanding of
the distinct structure–function properties of GSK-3 isozymes is
required for future design of isozymes-selective inhibitors.
Another important challenge toovercome for aGSK-3 inhibitor
to be converted in an effective drug for AD treatment is its spe-
ciﬁc brain distribution. The drug needs to cross the blood brain
barrier to exert its action in the regulation of exacerbated GSK-3
brain levels. Usually this is not an easy task for organic compounds
and/or peptides, moreover when oral bioavailability is the pre-
ferred administration route for chronic AD treatment. It is very
difﬁcult to balance the equilibrium between molecular lipophilic-
ity to enter into the brain and molecular hydrophilicity to be orally
administrated. That reason has ruled out several promising GSK-3
inhibitors from the race to the market. Determination of poten-
tial brain penetration should be incorporated in the ﬁrst stages of
GSK-3 inhibitors development.
Finally, our knowledge regarding human clinical side effects
of GSK-3 inhibitors is rather scarce since a limited number of
compounds have reached the clinical phase. Moreover, these com-
pounds are of distinct chemical structures; and thus differ in their
bioclinical and pharmacological properties (absorption, distribu-
tion,metabolism, etc.). It is thus difﬁcult to determine at this point
what adverse events will be commonly associated with inhibition
of GSK-3. Lithium is the only GSK-3 inhibitor that has been in
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Table 1 | GSK-3 inhibitors.
Inhibitors are sorted by mode of action (ATP competitive vs. non-ATP competitive) and source (natural vs. synthetic).
References: 1. Chuang and Manji (2007), 2. Mathew et al. (2008), 3.Williams et al. (2004), 4. Perez et al. (2003), 5. Bijur et al. (2000), 6.Wada et al. (2005), 7. Jin et al.
(2005), 8. Brewster et al. (2006) 9. Hongisto et al. (2003), 10. Nowak et al. (2005), 11. Bodnar and Wisner (2005), 12. Gómez-Ramos et al. (2006), 13. Martin et al.
(2009), 14. Kim et al. (2006), 15. Alabed et al. (2011), 16. Sato et al. (2004), 17. Meijer et al. (2000), 18. Gompel et al. (2004), 19. Selenica et al. (2007), 20. Peineau
et al. (2009), 21.Ying et al. (2008), 22. Li et al. (2011), 23. Ding et al. (2003), 24. Cross et al. (2001), 25. Culbert et al. (2001), 26. Takadera and Ohyashiki (2004), 27. Hu
et al. (2009), 28. Hongisto et al. (2008), 29. Facci et al. (2003), 30. Carmichael et al. (2002), 31. Mao et al. (2009), 32. Seira et al. (2011), 33. Bhat et al. (2003), 34. Shi
et al. (2004), 35. Gould et al. (2004), 36. Silva et al. (2008), 37. Kalinichev and Dawson (2011) 38. Noble et al. (2005), 39. Koh et al. (2007), 40. Mishra et al. (2007), 41.
Skardelly et al. (2011), 42. Petit-Paitel et al. (2009), 43. Leost et al. (2000), 44. Peineau et al. (2008), 45. Phiel et al. (2003) 46. Mettey et al. (2003), 47. Hamann et al.
(2007), 48. Rosa et al. (2008), 49. Luna-Medina et al. (2007), 50. Rosa et al. (2008), 51. Lipina et al. (2011), 52. Beaulieu et al. (2004), 53. Cuzzocrea et al. (2006), 54.
Ribe et al. (2005), 55. Sereno et al. (2009), 56. Perez et al. (2009), 57. Chen et al. (2004), 58. Kaidanovich-Beilin et al. (2004), 59. Shapira et al. (2007).
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clinical use for a signiﬁcant time. However, lithium lacks tar-
get speciﬁcity, and its adverse side effects and high toxicity do
not necessarily reﬂect events associated with inhibition of GSK-3
per se. AZD-1080 (AstraZeneca) and NP-12/Tideglusib (Noscria)
reached the clinic in 2006. AZD-1080 was abandoned as a drug
candidate due to nephrotoxicity observed in phase I clinical trials.
NP-12 is currently in phase IIb trials for Alzheimer’s disease and
paralysis supranuclear palsy, and no side effects/off targets effects
have been described at this time. Their distinct chemical structures
and/or different inhibition mode are most likely responsible for
the different clinical impacts observed with these two compounds.
Results from TAURUS andARGO studies will reveal the safety and
efﬁcacy of Tideglusib in humans. Meanwhile, an increasing num-
ber of GSK-3 inhibitors are being tested in preclinical models, and
it is anticipated that some will enter clinical trials.
CONCLUSION
As GSK-3 plays an important role in AD and some others unmet
diseases, more of them related to CNS, many inhibitors have been
discovered in the last years. Some of them have proven to be
effective in speciﬁc cellular and animal models of different CNS
pathologies. However, due to different hazards previously con-
sidered when GSK-3 is targeted, some risks should be avoid in
a GSK-3 inhibitor development. High values for IC50 and ATP-
competition when the compound binds to the enzyme, should
not be present in a GSK-3 inhibitor if we want that the molecule
become an effective drug. Amild inhibition of GSK-3 is indispens-
able to treat pathological states because it will be able to decrease
the exacerbatedGSK-3 function in the tissue affected by the disease
but the simultaneous decrease of activity in other healthy tissues,
will be compensate by alternative cellular mechanisms present in
the human being.
ATP non-competitive GSK-3 inhibitors such allosteric modu-
lators, substrate competitive or covalent inhibitors are emerging as
an alternative and promising approach for a safer use in the clinic.
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